Clinical Trial Update: Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 [Phase 1]

View source ↗

Summary

Phase 1/1b clinical trial evaluating NK cells engineered to express an affinity-enhanced T-cell receptor targeting NY-ESO-1 in patients with synovial sarcoma or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myxoid Liposarcoma
• Synovial Sarcoma

Drugs mentioned

• Affinity-enhanced T-cell receptor (TCR) NK cell therapy targeting NY-ESO-1

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Synovial Sarcoma, Myxoid/Round Cell Liposarcoma | Phase 1 | Status: RECRUITING